Objective response rate (ORR) and time to treatment failure (TTF) for BRAF v600 mutated metastatic melanoma (BRAF plus MM) patients receiving first-line (1L) targeted therapy (TT) or immunooncology (I-O) agents at US-based community oncology practices

被引：0
|
作者：
Luke, Jason J.
Ghate, Sameer R.
Kish, Jonathan
Lee, Choo Hyung
McAllister, Lindsay
Mehta, Sonam
Ndife, Briana
Feinberg, Bruce A.
机构：
[1] Univ Chicago, Comprehens Canc Ctr, Chicago, IL USA
[2] Novartis Pharmaceut, E Hanover, NJ USA
[3] Cardinal Hlth, Dallas, TX USA
[4] Cardinal Hlth Specialty Solut, Dublin, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e21516
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21516
引用
收藏
页数：2
相关论文
共 3 条
1